Abstract
There is evidence that HIV-positive injecting drug users benefit less than other risk groups from highly active antiretroviral therapy that has been available since 1996. In this multicentre European study the impact of the availability of highly active antiretroviral therapy on the progression rates to AIDS and death among injecting drug users with a documented date of HIV seroconversion is studied. After highly active antiretroviral therapy became available the risk of AIDS and death for injecting drug users decreased by 28% and 36%, which is less than has been reported for other risk groups.
Publication types
-
Comparative Study
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / mortality
-
Adult
-
Antiretroviral Therapy, Highly Active* / statistics & numerical data
-
Cohort Studies
-
Disease Progression
-
Europe / epidemiology
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / pathology
-
HIV Seropositivity / complications
-
HIV Seropositivity / drug therapy
-
HIV Seropositivity / pathology
-
Humans
-
Male
-
Registries
-
Risk Assessment
-
Substance Abuse, Intravenous / complications
-
Substance Abuse, Intravenous / virology*
-
Survival Analysis
-
Treatment Outcome